The silver linings in biotech’s wobbly market

A report from accounting firm BDO compares biotech’s tough times with the booming last few years — and points to some silver linings.

By Michael Gibney • April 4, 2023

Moderna exec: ‘There is nothing but global health’

How Chantal Friebertshäuser is helping lead Moderna’s plan to expand its global reach.  

By Alexandra Pecci • April 4, 2023

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

Staff shortages cause slowdowns in booming cell and gene therapy market

New reports highlight the need for more targeted biotech education curriculums to shore up a sustainable workforce.

By Karissa Waddick • April 3, 2023

All eyes turn to Karuna as it aims for an approval of a would-be blockbuster

In the red-hot race for new schizophrenia treatments, Karuna Therapeutics is close to an FDA submission.

By Kelly Bilodeau • April 3, 2023

Leaders wave a magic wand at pharma’s thorniest issues

The major challenges pharma leaders would solve with a quick flick of an imaginary wand.

By PharmaVoice staff • March 31, 2023

Digital biomarkers lay the groundwork for precision medicine beyond the bloodwork

Biomarkers are the hidden talent behind precision medicine, and finding them doesn't have to always come from a blood test — digital pioneers are finding another way.

By Michael Gibney • March 30, 2023

Predator and prey: Harnessing phages to fight antibiotic resistance

Phages, bacteria’s natural predator, could help combat the growing threat of superbugs. But can these therapies rise above antibiotic market woes?

By Karissa Waddick • March 30, 2023

Woman of the Week: Psilera’s Jackie von Salm

Psilera founder’s “third eye” approach to psychedelics ushers them into the therapeutic realm.

By Taren Grom • March 29, 2023

Seamless clinical trials were created to make studies easier — instead, they’ve become more complex

Experts weigh in on how companies can design better trials that merge two phases into one.

By Meagan Parrish • March 29, 2023

SCOTUS to decide ‘fundamental change’ in biologics patents with fate of Amgen v. Sanofi

The Supreme Court will now decide whether Amgen can protect Repatha as a whole class of drugs or whether Sanofi’s rival product Praluent can retain a place in the market.

By Michael Gibney • March 28, 2023

How one of the world’s sharpest inventors keeps the ideas coming. Hint: It’s not at work

Steve Quake, head of science for the Chan Zuckerberg Initiative, who’s had several “once-in-a-lifetime” ideas, provides advice on how to find inspiration.

By Alexandra Pecci • March 27, 2023

Cutting the cord — why streaming is a new frontier for pharma advertising

As streaming services proliferate, and more TV watchers buy in, there’s a new world of possibilities for DTC pharma marketing.

By Karissa Waddick • March 27, 2023

Biosimilars Market Poised for an Exciting Future

As the biologics industry approaches its next patent cliff, what is the state of the biosimilars market?

March 27, 2023

What would you fix with a ‘magic wand?’ Pharma leaders chime in about clinical trials

How life science execs would transform clinical trials with a little hocus pocus.

By PharmaVoice staff • March 24, 2023

Everyone says they’re patient-centric, but have they really walked the walk?

Life science leaders provide practical tips on how to create a sustainable patient-focused culture.

By Karissa Waddick • March 23, 2023

Woman of the Week: RIGImmune’s Susan Sobolov

RIGImmune’s president is setting her sights on an off-the-shelf viral vaccine.

By Taren Grom • March 22, 2023

SVB’s collapse had limited impact on biopharmas — but a broader financial crisis could change the landscape

Although many pharma and biotech companies had deposits at the failed bank, most have reported little to no exposure.

By Michael Gibney • March 21, 2023

Making the leap from the lab to the boardroom

Four academics-turned-executives share what they’ve learned about the pivot point between life sciences academia and entrepreneurship.

By Alexandra Pecci • March 21, 2023

‘The Last of Us’ might be fiction, but fungi are a looming threat

Fungal infections are a growing challenge for hospitalized patients, and new treatments are badly needed.

By Kelly Bilodeau • March 20, 2023

This biotech’s ‘Microsoft’ approach could change how we see gene therapy

The company’s using a unique component-based platform to develop functional cures for diseases, including HIV.

By Karissa Waddick • March 20, 2023

A biopharma CEO’s quest for global health equity has put him in the running for a Nobel Prize

Dr. Ryan Saadi, CEO of Tevogen Bio, is making good on a lifelong goal of bringing T cell therapies to people who need them.

By Taren Grom • March 17, 2023

Return of the megadeal: Pfizer’s Seagen buy has the industry asking if super-sized M&A is back

A $43 billion deal that doubles the pharma giant's cancer pipeline shows that M&A is back on the table in pharma.

By Michael Gibney • March 16, 2023

In the fallout from Aduhelm, Biogen’s leadership shakeup continues

The recent departure of neurodegenerative development head Samantha Budd Haeberlein is just the latest sign of a changing tide among Biogen’s post-Aduhelm leadership.

By Karissa Waddick • March 16, 2023

Woman of the Week: Novartis Gene Therapies’ Chris Fox

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...

By Taren Grom • March 15, 2023

A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch

To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.

By Michael Gibney • March 14, 2023